Drugs / FOY-305
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04451083 | Jul → Aug 2020 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04657497 | Nov 2020 → Mar 2021 | COVID-19 | Ono Pharmaceutical Co., Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOY-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04451083 ↗ |
| Known as | camostat mesilate | “BACKGROUND: In vitro drug screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells.” PMID 36163020 ↗ Sep 2022 |
| Route | Oral | “Multiple-dose of FOY-305 will be administered orally at 4 times/day.” NCT04451083 ↗ |